Why Farbe Firma is the Top Manufacturer of Dicyclomine HCl Injection
- Maulik Sudani
- 3 days ago
- 7 min read
Last Updated: June 4, 2026
TL;DR: Dicyclomine HCl Injection — a sterile aqueous solution of the anticholinergic antispasmodic dicyclomine (dicycloverine) hydrochloride, supplied most commonly as a 10 mg/mL solution in 2 mL ampoules for intramuscular administration — is a widely used agent for the relief of smooth-muscle spasm in functional gastrointestinal disorders such as irritable bowel syndrome, and in intestinal, biliary and renal colic. As a tertiary-amine antimuscarinic with an additional direct (musculotropic) relaxant action on smooth muscle, dicyclomine relieves painful spasm by blocking acetylcholine at muscarinic receptors and by relaxing the muscle wall directly. Because it is a parenteral antimuscarinic where the dose must be exact and the solution sterile and particulate-free, its safety depends on a precise stability-indicating assay, a tightly controlled impurity profile, low particulate and endotoxin, correct pH and robust ampoule container-closure integrity. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Dicyclomine HCl Injection at our Gujarat, India facility and supplies it to hospital pharmacy, emergency, gastroenterology and general-medicine services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Anticholinergic (antimuscarinic) antispasmodic with direct musculotropic action — Dicyclomine HCl Injection relieves smooth-muscle spasm in functional gastrointestinal disorders such as irritable bowel syndrome and in intestinal, biliary and renal colic, acting both by muscarinic-receptor blockade and by a direct relaxant effect on the smooth-muscle wall.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified ampoule filling lines, dedicated control of the stability-indicating assay, the impurity profile, pH, particulate and endotoxin for a parenteral antimuscarinic, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready ampoule packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Dicyclomine HCl Injection Demands a Premium Manufacturer
Dicyclomine HCl Injection occupies a dependable place in everyday acute and gastrointestinal care. It is the parenteral antispasmodic that clinicians turn to when a patient needs prompt relief from painful smooth-muscle spasm — the cramping of irritable bowel syndrome and other functional gastrointestinal disorders, and the colicky pain of intestinal, biliary or renal origin — and when oral therapy is impractical or too slow. Given by intramuscular injection, it acts to relax the spastic gut and relieve cramping pain. In each of these situations the patient is uncomfortable and often acutely distressed, the clinician needs a reliable response, and the dose delivered from each ampoule must be accurate, sterile and consistent from unit to unit.
That clinical reality places real demands on the manufacturer. Dicyclomine (dicycloverine) hydrochloride is a tertiary-amine antimuscarinic whose injectable solution must stay clear, correctly potent and free of degradation products across its shelf life. The assay must be exact — an under-potent ampoule fails the patient in pain, while a parenteral antimuscarinic given above its intended dose carries anticholinergic risk, so dose accuracy matters in both directions. The solution must be particulate-free, low in endotoxin, held at the right pH for intramuscular tolerability, and sealed in an ampoule whose integrity is verified. Choosing a Dicyclomine HCl Injection manufacturer that treats the stability-indicating assay, impurity profiling, particulate and endotoxin control, fill-volume accuracy and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Dicyclomine HCl Injection Manufacturer Apart
A world-class manufacturer of Dicyclomine HCl Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of dicyclomine hydrochloride together with tight control of its related-substance and degradation-product profile by HPLC, robust aseptic filling of an aqueous solution into ampoules with verified container-closure integrity and accurate fill volume, and tender-ready dossier support for a product procured largely through hospital-formulary, emergency-medicine and ministry-of-health channels. It starts with the active — pharmacopoeial-grade dicyclomine (dicycloverine) hydrochloride sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Formulation, filling and sealing then have to preserve both the assay and the dose. The bulk solution is compounded in water-for-injection at controlled pH, sterile-filtered through 0.22 µm membrane and filled aseptically into clear-glass ampoules under ISO Class 5 air. The filling and sealing parameters are locked in the master batch record, because for a parenteral antimuscarinic the assay and the fill-volume accuracy govern both the efficacy and the safety of every ampoule. Each ampoule is fusion-sealed and 100 % inspected for particulate matter, fill volume, seal quality and cosmetic defects; in-process and release testing confirm dicyclomine assay by validated HPLC, the related-substance profile, pH, clarity and colour of the solution, and endotoxin is held well within limits so the injection is safe for intramuscular administration.
Quality Systems Behind Every Dicyclomine HCl Injection
Every Farbe Firma Dicyclomine HCl Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of dicyclomine hydrochloride against USP, BP, IP or EP reference standards, control of related substances and degradation products by HPLC, pH and osmolarity, clarity and colour of the solution, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, fill-volume verification and container-closure integrity for the ampoule format. Certificates of analysis are issued with full traceability back to the API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated ampoule filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because a parenteral antimuscarinic must be dosed accurately and stay free of degradation, we treat the stability-indicating HPLC assay, the fill-volume result and the related-substance profile as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and the product is protected through its primary and secondary packaging.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Dicyclomine HCl Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across antispasmodic, gastrointestinal, analgesic, anti-infective, critical-care and supportive-care categories. For Dicyclomine HCl Injection specifically, we supply the 10 mg/mL solution in 2 mL ampoules under WHO-GMP conditions, with country-specific strengths, fill volumes and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay and impurity data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics. When a buyer needs Dicyclomine HCl Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, filling-line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the filling suite; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development, related-substance and degradation control, particulate and endotoxin control, fill-volume accuracy, container-closure integrity, photostability and shelf-life choices in real detail. For a parenteral anticholinergic antispasmodic given to patients in painful spasm, where assay accuracy, dose precision and impurity control directly govern both relief and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Dicyclomine HCl Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Dicyclomine HCl Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified ampoule filling lines, qualified water-for-injection systems, 100 % ampoule inspection and continuous environmental monitoring.
Which strengths and pack sizes of Dicyclomine HCl Injection do you supply?
Our standard presentation is a 10 mg/mL sterile aqueous solution in 2 mL ampoules (dicyclomine/dicycloverine hydrochloride). Custom strengths, fill volumes, ampoule counts per pack and country-specific artwork are available under contract manufacturing agreements.
Can Farbe Firma support country-specific registrations for Dicyclomine HCl Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
How does Farbe Firma assure the quality and safety of Dicyclomine HCl Injection?
We control the assay and related substances by stability-indicating HPLC against pharmacopoeial standards, verify pH, clarity and colour, confirm fill-volume accuracy, hold endotoxin well within limits by LAL, run particulate and sterility testing, 100 %-inspect every ampoule, verify container-closure integrity, and qualify each batch against ICH Q1A and ICH Q1B protocols.
What is the minimum order quantity for Dicyclomine HCl Injection contract manufacturing?
MOQs vary by ampoule size, fill volume, label complexity and dossier requirements. For the 2 mL presentation we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments